STRATA Skin Sciences Confirms Clinical Efficacy Of 308 NM Excimer Laser In Plaque Psoriasis

STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative dermatologic treatments, today highlights findings from a February 2026 systematic review and meta-analysis confirming the clinical efficacy of 308 nm Excimer laser in plaque psoriasis. Published in the Journal of Drugs in Dermatology by investigators from Georgetown University School of Medicine and the Department of Dermatology at MedStar Washington Hospital Center, the analysis evaluated clinical trials assessing the efficacy of the 308 nm excimer laser for plaque psoriasis. Across the included studies, patients were treated twice weekly for a minimum of 10 sessions, with outcomes measured using the Psoriasis Area and Severity Index (PASI). The study by Gratz, Ben, et al., titled, "Excimer Laser for Plaque Psoriasis: A Systematic Review and Meta-analysis" was published in the Journal of Drugs in Dermatology (JDD 25.2 (2026): e36-e37.).